The government is in the process of finalizing the 2021 Basic Policy for Economic and Fiscal Management and Reform (honebuto). This year’s policy will have a higher importance than previous ones because the drastic reforms of the drug pricing system…
BUSINESS
Life Science Institute’s Muse Cell Product Shows Safety, Tolerability in 2 Trials
Life Science Institute, a Mitsubishi Chemical Group company, said on April 23 that its multi-lineage differentiating stress enduring (Muse) cell product CL2020 demonstrated favorable safety and tolerability profiles in clinical trials for acute myocardial infarction and ischemic stroke. In the…
To read the full story
Related Article
- Life Science Institute to Establish New Field of Reparative Medicine with Muse Cells: President
May 20, 2021
- Life Science Institute to Begin Exploratory Study of Muse Cell Therapy for COVID-19-Associated ARDS
April 21, 2021
- Life Science Institute to Test Muse Cell Therapy in ALS
January 29, 2021
- Life Science Institute’s Muse Cell Therapy Effective in Epidermolysis Bullosa
July 30, 2020
- Life Science Institute Begins Muse Cell Trial for Spinal Injury; President Confident of Profitability
July 10, 2019
- Life Science Institute Initiates Exploratory Clinical Trial of Muse Cell Product for Epidermolysis Bullosa
December 21, 2018
- Life Science Institute to Initiate Exploratory Clinical Study of Muse Cell Product for Cerebral Infarction
September 4, 2018
- Life Science Institute Launches Clinical Study of IV Regenerative Medicine Product for Acute Myocardial Infarction
January 18, 2018
BUSINESS
- Astellas, Otsuka, Meiji Joining Workplace Vaccination Campaign
June 11, 2021
- NanoCarrier Gene Therapy VB-111 Enters PIII in Japan
June 11, 2021
- Global Pharma Market Grows to US$1.18 Trillion in 2020, with Humira Maintaining No. 1 Title: IQVIA
June 11, 2021
- US Biotech Zogenix Launches Japan Arm, Dravet Syndrome Med Filing Eyed in 2021
June 11, 2021
- Takeda Boasts 10-Plus Immune-Harnessing Compounds in Early Pipeline: Oncology Update
June 10, 2021
Last month, when discussing how life science manufacturers should react to the evolving pricing environment in Japan, I wrote about how manufacturers should align with stakeholders in government and the medical community on fair compensation for innovative, value creating, biopharmaceutical…
The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…